Compare
BeOne Medicines Ltd. vs Jazz Pharmaceuticals plc vs Perrigo Co PLC vs Alnylam Pharmaceuticals, Inc.
| Latest fiscal year | BeOne Medicines Ltd. ONC | Jazz Pharmaceuticals plc JAZZ | Perrigo Co PLC PRGO | Alnylam Pharmaceuticals, Inc. ALNY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $5.34B | $4.27B | $4.25B | $3.71B |
| Revenue growth (YoY) | +40.2% | +4.9% | -2.8% | +65.2% |
| Gross margin | 87.5% | n/a | 35.1% | 81.8% (computed) |
| Operating margin | 8.4% | -10.1% | -26.4% | 13.5% |
| Net margin | 5.4% | -8.3% | -33.5% | 8.4% |
| Net income | $286.93M | -$356.15M | -$1.43B | $313.75M |
| EPS (Diluted) | $0.19 | -$5.84 | -$10.29 | $2.33 |
| Operating cash flow | $1.13B | $1.36B | $238.50M | $524.08M |
| Free cash flow | $941.74M | $1.30B | $145.10M | $465.38M |
| Cash & equivalents | $4.55B | $1.39B | n/a | $1.66B |
| Total assets | $8.19B | $11.66B | $8.54B | $4.97B |
| Total liabilities | $3.83B | n/a | $5.60B | $4.18B |
| Shareholders' equity | $4.36B | $4.32B | $2.94B | $789.18M |
| Return on year-end equity | 6.6% | -8.2% | -48.6% | 39.8% |
| Shares outstanding | 1.44B | 61.44M | 137.60M | 132.38M |
Revenue, most recent five fiscal years
| Fiscal year | BeOne Medicines Ltd. | Jazz Pharmaceuticals plc | Perrigo Co PLC | Alnylam Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $5.34B Ended 2025-12-31 | $4.27B Ended 2025-12-31 | $4.25B Ended 2025-12-31 | $3.71B Ended 2025-12-31 |
| 1 year earlier | $3.81B Ended 2024-12-31 | $4.07B Ended 2024-12-31 | $4.37B Ended 2024-12-31 | $2.25B Ended 2024-12-31 |
| 2 years earlier | $2.46B Ended 2023-12-31 | $3.83B Ended 2023-12-31 | $4.66B Ended 2023-12-31 | $1.83B Ended 2023-12-31 |
| 3 years earlier | $1.42B Ended 2022-12-31 | $3.66B Ended 2022-12-31 | $4.45B Ended 2022-12-31 | $1.04B Ended 2022-12-31 |
| 4 years earlier | $1.18B Ended 2021-12-31 | $3.09B Ended 2021-12-31 | $4.14B Ended 2021-12-31 | $844.29M Ended 2021-12-31 |